Across TCGA pan-cancer cohorts, FAM187B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM187B data layer compared with 20 for mass-spec protein.
The strongest signal is observed in thyroid carcinoma (THCA), where higher FAM187B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM187B expression acts as an unfavorable survival marker.
THCA are the cancer types where FAM187B Mutation most reproducibly stratifies survival.